NLSP
Income statement / Annual
Last year (2023), NLS Pharmaceutics AG's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, NLS Pharmaceutics AG's net income was -$12.17 M.
See NLS Pharmaceutics AG’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$11,408.00 |
$11,408.00 |
$10,050.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$11,408.00 |
-$11,408.00 |
-$10,050.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$5.91 M
|
$8.98 M
|
$5.92 M
|
$99,580.00
|
$1.70 M
|
$1.44 M
|
$4.32 M
|
| General & Administrative
Expenses |
$5.90 M
|
$6,505.72
|
$5,941.17
|
$2,199.79
|
$3.30 M
|
$2.01 M
|
$1.44 M
|
| Selling & Marketing
Expenses |
$0.00
|
$6.49 M
|
$5.93 M
|
$2.20 M
|
$2.49 M
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$5.90 M
|
$6.49 M
|
$5.93 M
|
$2.20 M
|
$2.49 M
|
$2.01 M
|
$1.44 M
|
| Other Expenses |
$0.00 |
$10,045.00 |
-$17,323.00 |
-$328,365.00 |
$0.00 |
-$629,232.00 |
$0.00 |
| Operating Expenses |
$11.81 M |
$15.47 M |
$11.85 M |
$2.30 M |
$4.20 M |
$3.45 M |
$5.77 M |
| Cost And Expenses |
$11.81 M |
$15.48 M |
$11.86 M |
$2.30 M |
$4.20 M |
$3.45 M |
$5.77 M |
| Interest Income |
$0.00 |
$100.87 |
$68.13 |
$233.70 |
$819.71 |
$16,035.00 |
$890.40 |
| Interest Expense |
$145,153.00 |
$100,866.00 |
$68,134.00 |
$233,700.00 |
$819,711.00 |
$1.07 M |
$890,403.00 |
| Depreciation &
Amortization |
$11,408.00
|
$11,408.00
|
$10,050.00
|
$2.30 M
|
$4.20 M
|
$3.45 M
|
$5.77 M
|
| EBITDA |
-$11.80 M
|
-$15.47 M
|
-$11.85 M
|
$0.00
|
-$430,400.00
|
-$613,197.00
|
-$5.77 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$364,966.00
|
-$1.01 M
|
-$85,457.00
|
-$562,065.00
|
-$1.25 M
|
-$1.70 M
|
-$890,403.00
|
| Income Before Tax |
-$12.17 M |
-$16.50 M |
-$11.95 M |
-$2.86 M |
-$5.45 M |
-$5.15 M |
-$6.66 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
$2.00 |
-$226,508.00 |
-$2,299.37 |
-$4,197.04 |
$1.70 M |
-$5,766.72 |
| Net Income |
-$12.17 M |
-$16.50 M |
-$11.95 M |
-$2.86 M |
-$5.45 M |
-$5.15 M |
-$6.66 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-0.32 |
-0.84 |
-0.81 |
-0.59 |
-0.49 |
-0.44 |
-0.57 |
| EPS Diluted |
-0.32 |
-0.84 |
-0.81 |
-0.59 |
-0.49 |
-0.44 |
-0.57 |
| Weighted Average Shares
Out |
$38.18 M
|
$19.68 M
|
$14.75 M
|
$4.82 M
|
$11.14 M
|
$11.78 M
|
$11.78 M
|
| Weighted Average Shares
Out Diluted |
$38.18 M
|
$19.68 M
|
$14.75 M
|
$4.82 M
|
$11.14 M
|
$11.78 M
|
$11.78 M
|
| Link |
|
|
|
|
|
|
|
